HealthTech: Lübeck-based Perfood GmbH closed Series A1 funding round with participation of Boehringer Ingelheim Venture Fund

Perfood announced via LinkedIn:

“We are happy to have closed our Series A1 funding round and welcome Boehringer Ingelheim Venture Fund, investiere | Venture Capital and UV-Cap on board. With MillionFriends, Perfood has developed the leading personalized nutrition program. sinCephalea, our treatment for patients with episodic migraine, is set to become our first prescription digital therapy powered by personalized nutrition. We are looking forward with our new board members and observers Oliver Reuss, Nicholas Vetter, Martin Reuter and Michael Lütolf.”


About Perfood GmbH
At Perfood, we translate state-of-the-art data and medical science into therapy. We create software, that precisely identifies what actions need to be take on a personalized level, to prevent or fight diseases. Using sensors, lab results and holistic analyses, we derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. We call this approach digital therapeutics. A digital solution that is just as effective as a drug. But without side effects.


Logo (c) Perfood GmbH

IoT / Energy: Munich-based GreenCom Networks announces €12 million equity funding round led by Shell Ventures
Drones: GCA Altium advises SwissDrones on major capital raise

Ähnliche Beiträge